<?xml version="1.0" ?>
<document id="a4ffcadecc4b60c30df8f699c480724523272e62">
  <chunk id="a4ffcadecc4b60c30df8f699c480724523272e62.c0" text="First Discovery and Stucture-Activity Relationship Study of Phenanthroquinolizidines as Novel Antiviral Agents against Tobacco Mosaic Virus (TMV)">
    <entity charOffset="94-103" id="a4ffcadecc4b60c30df8f699c480724523272e62.c0.e0" ontology_id="CHEBI_22587" text="Antiviral" type="chemical"/>
    <entity charOffset="94-110" id="a4ffcadecc4b60c30df8f699c480724523272e62.c0.e1" ontology_id="CHEBI_22587" text="Antiviral Agents" type="chemical"/>
  </chunk>
  <chunk id="a4ffcadecc4b60c30df8f699c480724523272e62.c1" text="A series of phenanthroquinolizidine alkaloids 1-24 were prepared and first evaluated for their antiviral activity against tobacco mosaic virus (TMV). The bioassay results showed that most of these compounds exhibited good to excellent in vivo anti-TMV activity, of which compounds 1, 2, 15 and 16 displayed significantly higher activity than (R)-antofine and commercial Ningnanmycin at the same test condition. The substituents on the phenanthrene moiety play an important role for maintaining high in vivo antiviral activity.">
    <entity charOffset="36-45" id="a4ffcadecc4b60c30df8f699c480724523272e62.c1.e0" ontology_id="CHEBI_22315" text="alkaloids" type="chemical"/>
    <entity charOffset="95-104" id="a4ffcadecc4b60c30df8f699c480724523272e62.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="435-447" id="a4ffcadecc4b60c30df8f699c480724523272e62.c1.e2" ontology_id="CHEBI_28851" text="phenanthrene" type="chemical"/>
    <entity charOffset="473-477" id="a4ffcadecc4b60c30df8f699c480724523272e62.c1.e3" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="507-516" id="a4ffcadecc4b60c30df8f699c480724523272e62.c1.e4" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
  </chunk>
</document>
